Journal of
Italian
Banking
Association

year 100
 

Archive » January 2025 » Social Finance and BioTech: which role in supporting the development of innovative therapies

Social Finance and BioTech: which role in supporting the development of innovative therapies

Stefano Cosma, Luca Gambarelli, Daniela Pennetta
January 2025 - n. 1
Keywords: Funding gap, Atmp, terapie innovative, ricerca medica, finanza sociale
Jel codes: I13, G21, G24

The study analyses the operational-scientific peculiarities of the development process of innovative therapies (Atmps), showing how these make the clinical-economic evaluation complex and the traditional decision-making and intervention models of «Finance» ineffective. The study highlights how the intervention of Finance is limited and takes place, only, through debt/equity investments in BioTechs (Smes and startups). There is a need to coordinate the intervention of public, non-profit and private finance to reduce dispersion, be more consistent with the objectives of the various stakeholders and contribute to making investment in innovative therapies more sustainable, also through new models for evaluating the value created.

Interested in this paper?
Buy the issue